NASDAQ:SCPH scPharmaceuticals (SCPH) Stock Price, News & Analysis $4.08 +0.12 (+3.03%) Closing price 04:00 PM EasternExtended Trading$4.07 -0.01 (-0.37%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About scPharmaceuticals Stock (NASDAQ:SCPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get scPharmaceuticals alerts:Sign Up Key Stats Today's Range$3.99▼$4.1850-Day Range$2.24▼$4.2752-Week Range$1.94▼$5.65Volume264,990 shsAverage Volume374,471 shsMarket Capitalization$215.38 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingBuy Company Overview scPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing improved formulations of established oncology therapies through its proprietary SoluMatrix® microcrystal platform. By generating submicron drug particles, the company aims to enhance solubility, reduce infusion times and mitigate adverse reactions commonly associated with high-dose chemotherapy. Its technology is designed to repurpose widely used cytotoxic agents, offering the potential to address unmet needs in cancer treatment without the lengthy timelines required for novel drug discovery. The company’s lead candidate, SM-101, is a reformulated injectable version of gemcitabine being evaluated in Phase I/II studies for pancreatic and non-muscle invasive bladder cancer. SM-101 has received orphan drug designation from the U.S. Food and Drug Administration for pancreatic cancer, and early clinical results have demonstrated encouraging tolerability and preliminary efficacy signals. In addition to SM-101, scPharmaceuticals is advancing a second oncology program based on a reengineered formulation of paclitaxel, with the goal of reducing infusion-related side effects and broadening patient eligibility for treatment. Founded in 2009 and headquartered in Bridgewater, New Jersey, scPharmaceuticals conducts its clinical operations across the United States and Europe. The company is led by a management team with extensive experience in oncology development, regulatory affairs and pharmaceutical manufacturing. Under the leadership of CEO Suneel Chilukuri and supported by a board comprising former executives from major pharmaceutical firms, scPharmaceuticals is positioned to leverage its microcrystal technology to potentially improve standard-of-care cancer treatments and deliver value for patients and shareholders alike.AI Generated. May Contain Errors. Read More scPharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreSCPH MarketRank™: scPharmaceuticals scored higher than 83% of companies evaluated by MarketBeat, and ranked 172nd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingscPharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragescPharmaceuticals has received no research coverage in the past 90 days.Read more about scPharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for scPharmaceuticals are expected to grow in the coming year, from ($1.53) to ($1.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of scPharmaceuticals is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of scPharmaceuticals is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioscPharmaceuticals has a P/B Ratio of 15.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about scPharmaceuticals' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.64% of the float of scPharmaceuticals has been sold short.Short Interest Ratio / Days to CoverscPharmaceuticals has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in scPharmaceuticals has recently decreased by 12.02%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldscPharmaceuticals does not currently pay a dividend.Dividend GrowthscPharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.12 Percentage of Shares Shorted3.64% of the float of scPharmaceuticals has been sold short.Short Interest Ratio / Days to CoverscPharmaceuticals has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in scPharmaceuticals has recently decreased by 12.02%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for SCPH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added scPharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, scPharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.78% of the stock of scPharmaceuticals is held by insiders.Percentage Held by Institutions89.52% of the stock of scPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about scPharmaceuticals' insider trading history. Receive SCPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SCPH Stock News HeadlinesWith 42% stake, scPharmaceuticals Inc. (NASDAQ:SCPH) seems to have captured institutional investors' interestJune 12, 2025 | finance.yahoo.comscPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025May 22, 2025 | seekingalpha.comPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.July 9 at 2:00 AM | Paradigm Press (Ad)scPharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsMay 16, 2025 | finance.yahoo.comscPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2025 Earnings Call TranscriptMay 16, 2025 | insidermonkey.comScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectoryMay 16, 2025 | msn.comScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectoryMay 16, 2025 | msn.comQ1 2025 scPharmaceuticals Inc Earnings CallMay 16, 2025 | finance.yahoo.comSee More Headlines SCPH Stock Analysis - Frequently Asked Questions How have SCPH shares performed this year? scPharmaceuticals' stock was trading at $3.54 at the beginning of the year. Since then, SCPH shares have increased by 15.3% and is now trading at $4.08. How were scPharmaceuticals' earnings last quarter? scPharmaceuticals, Inc. (NASDAQ:SCPH) released its earnings results on Wednesday, May, 14th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.06. The company earned $11.75 million during the quarter, compared to the consensus estimate of $11.63 million. scPharmaceuticals had a negative trailing twelve-month return on equity of 594.07% and a negative net margin of 216.24%. Read the conference call transcript. When did scPharmaceuticals IPO? scPharmaceuticals (SCPH) raised $96 million in an initial public offering on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. How do I buy shares of scPharmaceuticals? Shares of SCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of scPharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that scPharmaceuticals investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), AU Optronics (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/14/2025Today7/09/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SCPH CIK1604950 Webwww.scpharma.com Phone(617) 517-0730FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for scPharmaceuticals$14.00 High Price Target$18.00 Low Price Target$12.00 Potential Upside/Downside+243.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$85.15 million Net Margins-216.24% Pretax Margin-216.24% Return on Equity-594.07% Return on Assets-73.54% Debt Debt-to-Equity Ratio3.86 Current Ratio5.48 Quick Ratio4.61 Sales & Book Value Annual Sales$36.33 million Price / Sales5.93 Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book15.11Miscellaneous Outstanding Shares52,790,000Free Float50,269,000Market Cap$215.38 million OptionableOptionable Beta0.38 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:SCPH) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding scPharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share scPharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.